John H. Leaman, MD is currently the Chief Financial Officer at Cellarity Inc. During his tenure, he has helped oversee the close of a large pharma partnership, as well as leading the company‘s Series D crossover financing. Prior to joining Cellarity in 2023, Dr. Leaman served as the Chief Financial Officer and Chief Business Officer at Impel Pharmaceuticals LLC, where he helped lead the company’s IPO in 2021. Before that, Dr. Leaman served as the Chief Financial Officer and Head of Corporate Development at Selecta Biosciences, Inc. and as Head of Corporate Development at InfaCare Pharmaceutical Corporation until it was acquired by Mallinckrodt plc in 2017. Earlier, Dr. Leaman was the Chief Financial Officer of Medgenics, Inc. and previously held senior roles at Shire plc and Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies. He began his career serving a range of life sciences companies as an Associate Principal at McKinsey & Company.

Dr. Leaman received an MD from the Perelman School of Medicine at the University of Pennsylvania, an MBA from the Wharton School at the University of Pennsylvania, a BA in Psychology, Philosophy and Physiology from Oriel College, University of Oxford while completing a Rhodes Scholarship, and a BS in Biology from Elizabethtown College.